Gutierrez M, Lam WS, Hellmann MD, Gubens MA, et al. Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results. Nat Med 2023 Jul 10. doi: 10.1038/s41591-023-02385.
PMID: 37429923